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1. Introduction 
The porphyrias are metabolism diseases caused by the deficiency of a specific enzyme in the 
heme biosynthetic pathway. Porphyrias have been classified into bone marrow and liver 
types on the basis of the predominant site of porphyrin production site. Recent classification 
of porphyrias shows acute porphyria and cutaneous porphyria according to the condition of 
signs (Table 1). Eryhtropoietic protoporphyria (EPP; OMIM 177000) is an autosomal 
dominant disease of porphyrin metabolism caused by decreased activity of the 
ferrochelatase (FECH; E.C. 4.99.1.1) that is the terminal enzyme in the heme biosynthetic 
pathway (Fig. 1). This type of porphyria was first described in 1953 by Kosenow and Treibs 
and this description was completed in 1961 by Magnus et al.1 Decrease in FECH activity 
causes excess protoporphyrin induction, leading to photosensitivity of the skin and liver 
dysfunction. Photosensitivity starting from childhood makes quality of life low and liver 
dysfunction may lead to hepatic failure and death. In this session, we describe (1) clinical 
features of EPP, (2) genetic characteristics of EPP, and (3) mice models of EPP. 
2. The clinical features of EPP 
2.1. Skin 
Suspicion of EPP should be raised by the history of screaming or skin pain in a child on 
going outdoors.2 However, it is very difficult to suspect EPP if clinical manifestation are 
minimum. The characteristics of photosensitivity in EPP are first a burning, stinging 
sensation appearing immediately at sun exposure followed by erythema, edema and 
purpura.1 We reported a 1-year-old male infant with EPP who showed only erythema after 
sun exposure (Fig. 2).3 Infant patients are unable to complain the abnormal sensations and 
pain. Cutaneous signs are characterized with erythema, swelling, papules, vesicles, small 
blood blisters, crusts, and scars. Scar, the most distinct skin lesion, is small, polygonal or 
linear, depressed or slightly elevated (Figs. 3 and 4). With the progression of the disease and  
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Figure 1. Heme biosynthetic pathway. 
 
Figure 2. Clinical picture of a 1-year-old male baby with erythopoietic protoporphyria. Redness and 
swelling were seen on the face. 
Glycine +
Succinyl CoA
Delta aminolevulinic
acid (ALA)
Porphobilinogen
(PBG)
Hydroxymethylbilane
Uroporphyrinogen I
Coproporphyrinogen I
Uroporphyrinogen III
Coproporphyrinogen III
Protoporphyrinogen IX Protoporphyrin IX Heme
Ferrochelatase
Fe 2+
 
Eryhtropoietic Protoporphyria 89 
 
Figure 3. Clinical picture of a 14-year-old boy with erythopoietic protoporphyria. Depressed scars were 
seen on the face. 
if sun exposure is not avoided, chronic lesions develop progressively with skin thickening 
(waxy lichenification on the dorsa of the hands) and scarring (pseudorhagades formation in 
the lips).1 
Minder performed a systematic review of treatment options for dermal photosensitivity in 
EPP.4 Sixteen of 25 relevant studies dealed with -carotene. However, the results from  
-carotene were strongly contradictory and efficacy was inversely correlated with study 
quality.4 Afamelanotide, an a-melanocyte-stimulating hormone analogue, was reported to 
be effective for EPP.5 Afamelanotide, making melanin density of the skin increase, was 
effective for photosensitivity from artificial light and sunlight in 5 EPP patients.5 Moreover, 
Petersen reported that oral treatment with a high daily dosage of zinc sulphate during the 
spring and summer reduced light sensitivity and pain in 71% of 14 EPP patients.6 They 
speculated that zinc treatment in EPP patients may have provided antioxidant protection of 
cellular membranes against the deleterious photodynamic effects of protoporphyrin IX 
(PPIX) accumulation.6 Photoprotection against visible light that absorbs PPIX is still a 
mainstream in the care of EPP patients, although these novel approaches were reported. 
However, some reports raised awareness about vitamin D deficiency due to sun avoidance 
in EPP. Spelt reported that 46% of 48 Dutch EPP patients showed decreased level of serum 
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Figure 4. Clinical picture of a 14-year-old boy with erythopoietic protoporphyria. Whitish swelling 
scars were seen on the back of the hand. 
25-hydroxyvitamin D.7 Vitamin D deficiency was high in male patients and correlated with 
the severity of EPP.7 Holme also reported that 17% was deficient and 63% was insufficient in 
serum 25-hydroxyvitamin D levels of 201 United Kingdom (UK) patients with EPP.8 Then, 
we should care for vitamin D deficiency in EPP patients performing strict photoprotection.   
2.2. Liver 
Mild abnormalities of liver function may be detected in about 10% of patients of EPP and 
liver failure affects about 5-20%.2, 9 Excess PP with any origin is excreted by the liver into bile 
and enters an enterohepatic circulation.10 Excess PP becomes insoluble in bile and exerts 
cholestatic effects, structural changes from mild inflammation to fibrosis and cirrhosis.10 
Liver diseases include cholelithiasis, gallstones, biochemical abnormalities (aspartate amino 
transferase (AST), alanine amino transferase (ALT), gamma-glutamyl transpeptidase 
(gamma-GTP), alkaline phosphatase (ALP)), cirrhosis, and terminal liver failure. PP 
deposition in hepatocytes is invariable, whereas histological evidence of damage is less 
common; electron microscopy shows ultrastructural damage in most patients with EPP.10 
Liver transplantation for liver failure in EPP patients started in 1980. Dowman investigated 
5 UK cases receiving liver transplant for EPP-related liver diseases.11 Two patients died at 44 
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and 95 months from causes unrelated to liver disease, while 3 patients were alive at 22.4 
years, 61 months and 55 months after liver plant.11 In spite of a good long-term survival, a 
high rate of postoperative biliary stricturing requiring multiple biliary interventions was 
seen.11 Wahlin also investigated that 35 liver transplants for protoporphyric liver disease in 
31 European patients between 1983 and 2008.12 The overall rate of disease recurrence in the 
graft was high (69%), although they showed good survival rates, 77% at 1 year and 66% at 5 
and 10 years.12 
As liver transplant does not correct the constitutional deficiency of FECH, there is a risk of 
recurrence of liver disease even after liver transplant due to continuing overproduction of 
protoporphyrin.9 Then, bone marrow transplantation may be considered in liver allograft 
recipients in the future. 
2.3. Biochemistry and blood test 
Increase of PP in the blood and stool is the most specific in EPP. However, urinary 
porphyris (uroporphyrin, coproporphyrin, porphobirinoge, -aminolevulic acid) remain as 
normal levels. Many patients with EPP have an apparent mild anemia with a microcytic 
hypochromic blood film.2 However, administration of iron is not recommended since iron 
sometimes exacerbate the porphyria. 
3. Genetic characteristics of EPP 
EPP is a disease caused by decreased activity of the ferrochelatase (FECH; E.C. 4.99.1.1) that 
is the final enzyme in the heme biosynthetic pathway. The FECH gene contains 11 exons and 
spans about 45 kb of genomic DNA on chromosome 18q21.3, and its cDNA sequence 
encodes for 423 amino acids (GenBank no. D00726). The mode of inheritance is primarily 
autosomal dominant, and the clinical penetrance is low. In the dominant type of EPP, 
different degrees of enzyme deficiency are seen between patients and asymptomatic gene 
carriers, i.e., symptomatic patients usually have less than 50% of the normal activity, 
whereas the asymptomatic ones show approximately 50% of the normal activity.13 
Gouya reported that (1) coinheritance of a FECH gene defect and a wild-type low-expressed 
allele is generally involved in the clinical expression of EPP; (2) the low-expressed allelic 
variant was associated with a partial 5’ haplotype [-251G IVS1-23T IVS2satA9] that may be 
ancestral and was present in an estimated 10% of a control group of Caucasian origin; and 
(3) haplotyping allows the absolute risk of developing the disease to be predicted for those 
inheriting FECH EPP mutations.13 Mutations of FECH gene in EPP are highly heterogenous 
and specific for each family members. Minder studied the association between “null allele” 
mutation and liver complication in 1112 EPP patients.14 All 18 EPP patients who had severe 
liver complication showed a “null allele” mutation, whereas 20 patients with a missense 
mutation did not have liver complication till the time of study.14 This study indicates that a 
significant genotype-phenotype correlation between "null allele" mutation and liver 
disorder in EPP. 
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Genetic variants in the FECH gene include more than 175 mutations and 538 single-
nucleotide polymorphisms (SNPs).15 The functionality of these SNPs may reduce the level of 
transcription of the FECH gene contributing to the triggering of EPP.15 A common low 
expression allele, IVS3-48T>C, is seen in 10% of European Caucasians. Most EPP patients 
(~90%) have a FECH loss-of-function mutation in cis and the common low expression allele 
in trans, resulting in 15-25% of normal FECH activity.16 As described above, mutations of 
FECH gene in EPP are highly family-specific. There have been many variations of FECH 
gene mutations reported in various countries.  
Nakano firstly identified two novel mutations in two Japanese families using direct 
sequence analysis of the entire coding region of the FECH gene.17 The proband in the first 
family was heterozygous for a 3-bp deletion from nucleotide positions 853 to 855 in exon 8, 
designated delCAA853.17 Pedigree analysis of the other family members showed that the 
mother and two sisters, all asymptomatic, were heterozygous for this mutation.17 Restriction 
fragment polymorphism analysis indicated that the proband was homozygous for the IVS3-
48C polymorphism, while other family members, asymptomatic carriers, had a wild-type T 
at position IVS3-48 in trans to the mutated allele.17 They concluded that the IVS3-48C 
polymorphism in one allele and a deleterious mutation (delCAA853) in the other allele 
caused a phenotype of EPP. In the second family, all three members having symptoms of 
EPP showed the C683→T mutation in combination with the trans IVS3-48C polymorphism.17 
These results from the analysis of two Japanese families indicated that the intronic IVS3-48C 
polymorphism in the non-mutated allele is a distinct determinant of the EPP phenotype. 
Their further investigation of the frequency of IVS-48C polymorphism in 104 Japanese 
controls revealed that the genotypic frequency of IVS3-48C/C was 0.192, that was over 10 
times those of European countries (0-0.017).17 These differences may affect the prevalence 
and penetrance of EPP in Japan.  
In UK, Whatley identified large deletions of the FECH gene in 19 (58%) of 33 unrelated UK 
patients with EPP using gene dosage analysis by quantitative PCR; (1) six deletions (c.1-
7887-IVS1+ 2425insTTCA; c.1-9629-IVS1+ 2437; IVS2-1987-IVS4+352del; c.768-IVS7+ 244del; 
IVS7+2784-IVS9+108del; IVS6+2350-TGA+95del), (2) five breakpoints in intronic repeat 
sequences (AluSc, AluSq, AluSx, L1MC4), and (3) large insertion-deletion (Del Ex3-4).18 
Berroeta reported a UK case with late onset of EPP and identified a mutation (1001C→T; 
P334L).19 
In Canada, Pierro identified a 10,376 bp deletion (c.1-7887_67+2422del) including a portion 
of the upstream intergenic region, the promoter, the exon 1 and a portion of intron 1 in a 
Canadian EPP patient of Italian origin.20 Li also reported that a Canadian EPP patient had a 
novel large deletion [c.1-9628_67+2871del12566 bp] and three polymorphisms [c.1-251A>G, 
c.68-23C>T and c.315-48T>C] in trans to the deletion in FECH gene.21 
In China, Zhou identified a novel IVS1+1G→C mutation of the FECH gene in a Chinese EPP 
family.22 Fong identified a recurrent splice site mutation, c.67+1G>C, and a novel nonsense 
mutation, p.Y191X, in 2 unrelated Chinese families.23 Their investigation revealed that the 
allele frequency of IVS3-48C in Hong Kong population (28%) was lower than that of 
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Japanese population but higher than that of European populations.23 Ma identified a novel 
splicing FECH mutation, IVS3+1G→A, and IVS3-48C polymorphism in a Chinese EPP 
family.24 
In Argentina, Parera detected three novel and two previously described mutations in five 
Argentinean EPP families; (1) a deletion (451delT) producing a stop codon located 18 codons 
downstream from the mutation, (2) IVS1-2A>G leading to exon 2 skipping, (3) IVS4-2A>G, 
which causes the loss of the first 48 bp of exon 5, (4) C343T, and (5) 400delA.25 Colombo’s 
study of 19 Argentina EPP patients identified three novel (p.S222N; p.R298X and p.R367X) 
and seven already known (g.12490_18067del; p.R115X; p.I186T; c.580_584delTACAG; 
c.598+1G>T; p.Y209X and p.W310X) and indicated the possibility of c.315-48C variant in 
trans to the mutated allele as a sufficient trigger of EPP.15 
In Spain, Herrero reported that three novel mutations (IVS4+1delG, 347-351delC, and 
130_147dupl 18) and IVS3-48C low-expression allele in ten of 11 EPP patients.26 They also 
estimated the frequency of the IVS3-48C allele among 180 nonporphyric Spanish individuals 
as 5.2%.26 In South Africa, Parker identified ten sequence variations; IVS3-48T ⁄ C 
polymorphism, five further polymorphisms, a 5-bp deletion in exon 7 (757_761delAGAAG), 
two previously described splice-site mutations (IVS3+2T>G and IVS7+1G>A), and a novel 7-
bp deletion in exon 4 (356_362delTTCAAGA).27 In Portugal, Morais identified 
heterozygosity for a novel mutation (c.1052delA) in FECH gene of two children, and 
heterozygosity for the hypomorphic allele IVS3-48T>C in two children and asymptomatic 
mother.28 
Recently, an association of EPP and palmar keratoderma has been reported. Méndez 
detected a homozygous inheritance of a novel missense mutation Q285R, a homozygous 
A-to-G transition, c.854A>G, in the FECH gene in a Caucasian family of EPP associated 
with palmar keratoderma.29 Minder also reported a case of an association of EPP and 
palmar keratoderma who had a novel homoallelic missense mutation (p.Ser318Tyr) in the 
FECH gene.30 Their Palestinial (Jordanian) parents were heterozygous for the S318Y 
mutation.30 
4. Mice models of EPP 
Mice models of EPP are useful to investigate the effects of FECH on iron metabolism in EPP. 
Lyoumi investigated hematologic and iron status in FECH-deficient Fechm1Pas mutant 
mice.31 Their mice had microcytic hypochromic anemia without ringed sideroblasts, little or 
no hemolysis, and no erythroid hyperplasia, whereas the mice showed no tissue iron 
deficiency but did a redistribution of iron stores from peripheral tissues to the spleen, with a 
2- to 3-fold increase in transferrin expression of mRNA and protein levels.31 Using 
Fechm1Pas mutant mice with the BALB/c and C57BL/6 backgrounds, Lyoumi demonstrated 
that BALB/c  backgrounded Fechm1Pas mice had more severe cholestasis, fibrosis with 
portoportal bridging, bile acid regurgitation, sclerosing cholangitis, and hepatolithiasis as 
compared with the mice with C57BL/6 background.32 
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5. Conclusion 
EPP is an autosomal dominant disease of porphyrin metabolism that is characterized with 
photosensitivity and liver disease. We have reviewed recent advances of clinical features of 
EPP, genetic characteristics of EPP, and mice models of EPP. Further studies of genetic 
analysis and FECH-deficient mice will provide us the new strategy for the treatment of EPP. 
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